News
OCUL
--
0.00%
--
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 4d ago
Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences
Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate at the following con...
Business Wire · 05/26 12:00
Insider Trends: Ocular Therapeutix Insider Extends 90-Day Selling Trend
MT Newswires · 05/21 21:12
Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options
Zacks.com · 05/20 12:46
Kamunting Street Capital Management, L.P. ...
GuruFocus News · 05/18 22:38
Global Retinal Drugs and Biologics Market Statistics, Cagr, Outlook, And Covid-19 Impact 2021 - 2023
May 12, 2021 (Heraldkeepers) -- The Retinal Drugs and Biologics market report provides a detailed analysis of global market size, regional and country-level...
Heraldkeepers · 05/12 10:56
Ocular Sealants and Glues Market Opportunities, Growth and Forecasting for next Upcoming Year Until 2029 | Ocular Therapeutix Inc., Johnson & Johnson, Reliance Life-Sciences & so on…
May 10, 2021 (MARKITWIRED via COMTEX) -- Future Market Insights (FMI) adopted a multidisciplinary approach during the pandemic-era to focus on the growth and...
Markitwired · 05/10 07:19
Sustained Release Ocular Drug Delivery Systems Market Growth Opportunities, Key Driving Factors, Market Scenario and Forecast 2021 - 2028 By Ameco Research
pune, India, Mon, 10 May 2021 00:04:22 / Comserve Inc. / -- The global Sustained Release Ocular Drug Delivery Systems market is segmented by company, region...
Comserve · 05/10 04:07
Versant Venture Management, LLC Buys Passage Bio Inc, Sells CRISPR Therapeutics AG, Inari ...
GuruFocus News · 05/07 14:38
--Berenberg Bank Adjusts Ocular Therapeutix PT to $26 From $27, Maintains Buy Rating
MT Newswires · 05/07 11:19
Ocular Therapeutix (OCUL) Receives a Rating Update from a Top Analyst
In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on Ocular Therapeutix (OCUL). The company's shares closed last Thursday
SmarterAnalyst · 05/07 10:47
Newsflash: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Have Been Trimming Their Revenue Forecasts
Simply Wall St. · 05/07 07:12
8-K: OCULAR THERAPEUTIX, INC
(EDGAR Online via COMTEX) -- 0001393434 false 0001393434 2021-05-05 2021-05-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 05/05 22:43
Ocular Therapeutix Q1 EPS $(0.24) Misses $(0.21) Estimate, Sales $7.34M Miss $7.64M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 41.46 percent increase over losses of $(0.41) per share
Benzinga · 05/05 20:15
Ocular Therapeutix EPS misses by $0.04, misses on revenue
Ocular Therapeutix (OCUL): Q1 GAAP EPS of -$0.24 misses by $0.04.Revenue of $7.34M (+181.2% Y/Y) misses by $0.51M.DEXTENZA® Achieved Quarterly Record of 16,634 Billable Units Sold to End Customers, Representing
Seekingalpha · 05/05 20:03
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the first quarter of 202...
Business Wire · 05/05 20:01
Ocular Therapeutix, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Ocular Therapeutix, Inc. (NASDAQ:OCUL) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 05/05 18:30
-- Earnings Flash (OCUL) OCULAR THERAPEUTIX Reports Q1 Revenue $7.3M, vs. Street Est of $7.85M
MT Newswires · 05/05 16:07
Surgical Sealants and Adhesives Market Research Study 2021 Insights with COVID-19 Impact Analysis by 2020
May 05, 2021 (Heraldkeepers) -- The Surgical Sealants and Adhesives Market are segmented on the lines of its application, product, indication and regional....
Heraldkeepers · 05/05 12:52
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.